BioAtla, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded no collaboration or other revenue during the quarter, a stark contrast to the $11 million generated in the same period last year. For the nine months ended September 30, 2025, total revenue also remained at zero, compared to $11 million for the same period in 2024. The company’s net loss for the third quarter was $15.8 million, up from a loss of $10.6 million in the prior year, while the nine-month net loss decreased slightly to $49.8 million from $54.9 million.
The financial position of BioAtla has deteriorated, with total assets dropping to $15.9 million as of September 30, 2025, down from $52.4 million at the end of 2024. Cash and cash equivalents plummeted to $8.3 million from $49 million, reflecting a net decrease of $40.7 million in cash during the nine-month period. The company’s accumulated deficit has now reached $535.9 million, indicating ongoing financial strain as it continues to invest heavily in research and development.
Operationally, BioAtla has undergone significant restructuring, including a 30% reduction in workforce implemented in March 2025, aimed at improving its cost structure. This restructuring has contributed to a decrease in operating expenses, which fell to $50.1 million for the nine months ended September 30, 2025, down from $68.7 million in the previous year. Research and development expenses specifically decreased to $35.6 million from $51.4 million, attributed to lower enrollment in clinical trials and reduced overall expenses as the company completes its Phase 2 trials.
Looking ahead, BioAtla faces substantial uncertainty regarding its ability to continue as a going concern. The company has indicated that its current cash reserves may not be sufficient to fund operations for the next twelve months, raising doubts about its financial viability. Management plans to seek additional funding through equity or debt financing, but acknowledges that these efforts may not be successful. The company’s future will largely depend on the successful development and commercialization of its product candidates, which remain in clinical trials.
About BioAtla, Inc.
BioAtla, Inc. is a clinical-stage biopharmaceutical company specializing in conditionally active biologics (CABs), a novel class of antibody-based therapeutics targeting solid tumor cancers. Its proprietary CAB technology exploits tumor microenvironment acidity to selectively bind cancer cells, reducing off-tumor toxicity. BioAtla develops monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and CAR-T therapies, focusing on improving cancer treatment efficacy and safety through enhanced tumor specificity.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.